Committee for Advanced Therapies (CAT)

The Committee for Advanced Therapies (CAT) is the committee at the European Medicines Agency that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products (ATMPs) and following scientific developments in the field. It is a multidisciplinary committee, gathering together some of the best available experts in Europe.

It was established in accordance with Regulation (EC) No 1394/2007 on ATMPs.

• See the full overview of the CAT's role.

Composition

The members of the CAT are appointed for a renewable period of three years. The chair and vice-chair are elected from its members for a term of three years, which may be renewed once.

The CAT is composed of:

• five members or co-opted members of the Committee for Medicinal Products for Human Use (CHMP), with their alternates. These members are appointed by the CHMP itself;
• one member and one alternate appointed by each European Union (EU) Member State that is not represented by the members and alternates appointed by the CHMP;
• two members and two alternates appointed by the European Commission to represent clinicians;
• two members and two alternates appointed by the European Commission to represent patient associations.

Meeting calendar

• See full meeting plan for this year.